Telix Pharmaceuticals (ASX: TLX) Delivers 21% Revenue Growth as Precision Medicine Business Nears US$1 Billion Milestone

Telix Pharmaceuticals (ASX: TLX) has continued to build momentum as one of Australia’s largest commercial-stage biotechnology companies, reporting a 21% increase in quarterly revenue while forecasting annual revenue and other income will exceed US$1 billion for the first time.

The strong result reflects growing demand for the company’s precision medicine portfolio, particularly its prostate cancer imaging products in the United States, where radiopharmaceuticals are becoming an increasingly important part of cancer diagnosis and treatment.

Live Stock data: Source Tradingview

For the quarter ended 30 June 2026, Telix generated total group revenue of US$247 million, up from US$204 million a year earlier. The company’s Precision Medicine division remained the primary growth engine, with revenue rising 30% year-on-year to US$202 million, offsetting a modest decline in its Telix Manufacturing Solutions business.

The result keeps Telix on track to reach the upper end of its core product revenue guidance of US$950 million to US$970 million for the full year, while total revenue and other income are now expected to exceed US$1 billion. That figure also includes a US$40 million non-refundable upfront payment received through its strategic collaboration with U.S. biotechnology company Regeneron.

Crossing the US$1 billion threshold represents an important milestone for Telix. Rather than relying primarily on external funding, the company is increasingly using commercial cash flow to fund research, expand manufacturing and progress multiple late-stage clinical programs.

That strategy is becoming increasingly important as precision medicine reshapes cancer care. Radiopharmaceuticals combine advanced imaging with targeted therapies, allowing doctors to identify tumours more accurately and deliver radiation directly to cancer cells while limiting damage to surrounding healthy tissue. Industry analysts expect the global radiopharmaceutical market to expand steadily over the coming decade as personalised cancer treatments gain wider adoption.

 (Source: Telix, industry market research.)

Beyond commercial performance, Telix continued to advance several clinical programs during the quarter.

Its prostate cancer therapy TLX591-Tx achieved regulatory alignment with the U.S. Food and Drug Administration, allowing progression toward the second stage of its global Phase 3 ProstACT trial, subject to final Investigational New Drug review.

Telix also completed patient enrolment in the Phase 2 OPTIMAL-PSMA study evaluating TLX597-Tx, dosed the first patient in the pivotal Phase 3 LUTEON study for kidney cancer, and began enrolling patients in the IPAX BrIGHT trial for recurrent glioblastoma, one of the most aggressive forms of brain cancer.

On the diagnostics side, Telix’s brain cancer imaging product Pixclara moved a step closer to potential approval after the U.S. FDA accepted its resubmitted New Drug Application and assigned a Prescription Drug User Fee Act decision date of 11 September 2026. Meanwhile, the company continues preparing a resubmission for Zircaix, its kidney cancer imaging candidate, under the FDA’s Breakthrough Therapy designation.

Supporting that expanding pipeline is continued investment in manufacturing. Through Telix Manufacturing Solutions, the company has strengthened isotope production capabilities across Melbourne, Brussels and Yokohama, helping reduce one of the industry’s biggest challenges, maintaining reliable supplies of short-lived medical radioisotopes.

Managing Director and Group Chief Executive Officer Dr Christian Behrenbruch said commercial execution continued to support broader growth ambitions.

“We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix’s market leadership, built on clinical differentiation, supply chain resilience and commercial execution.”

He added:

“During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value.”

To support that expansion, Telix increased planned research and development spending to between US$230 million and US$270 million for 2026. The company also refinanced its balance sheet through the issue of US$600 million in convertible bonds maturing in 2031, replacing existing 2029 debt and extending its funding profile.

With commercial revenue continuing to grow, multiple Phase 3 studies underway and several regulatory decisions expected over the next 12 months, Telix is increasingly transitioning from a high-growth biotechnology company into a diversified global precision medicine business with both commercial scale and a broad late-stage development pipeline.

Sources: Telix Pharmaceuticals Q2 2026 Results and Operational Update; U.S. FDA; Regeneron collaboration announcement.